AHA April 20, 2021

The Accelerating COVID 19 Therapeutic Interventions and Vaccines (ACTIV) initiative will enroll up to 13,500 adults aged 30 and over in a Phase 3 clinical trial to evaluate whether certain drugs approved for other conditions safely and effectively treat mild-to-moderate COVID-19, the National Institutes of Health announced yesterday. 

With funding from the American Rescue Plan Act, the ACTIV-6 trial will test up to seven drugs administered orally or by inhaler at home, with a focus on enrolling patients...

Today's Sponsors

Teladoc Health
Premier
TripleTree

Today's Sponsors

SalesSparx
Canton & Company

Today's Sponsor

HLTH

 
Topics: Uncategorized
Decentralized Clinical Trials: Surviving & Thriving in the Clinical Research World of COVID-19
Genetic Data Identifies Drug Targets to Treat Early COVID-19
Spurred by the pandemic, AI is driving decentralized clinical trials
The Future Of Clinical Trials: How AI, Big Tech, & Covid-19 Could Make Drug Development Cheaper, Faster, & More Effective
5 AI lessons from pharma world learned during Covid-19